Cargando…

The Jak Tree

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	1889
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238798/ https://www.ncbi.nlm.nih.gov/pubmed/36492188

Ejemplares similares

JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing
por: Mahe, Etienne, et al.
Publicado: (2019)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy
por: Koppikar, Priya, et al.
Publicado: (2012)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
por: Ferrao, Ryan D, et al.
Publicado: (2018)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

JAK inhibitors for refractory lymphoma
por: Kimura, Hiroshi
Publicado: (2018)

Basic Mechanisms of JAK Inhibition
por: Lin, Chung MA, et al.
Publicado: (2020)

JAK inhibitors and COVID-19
por: Levy, Gabriel, et al.
Publicado: (2022)

The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Tubulosine selectively inhibits JAK3 signalling by binding to the ATP‐binding site of the kinase of JAK3
por: Kim, Byung‐Hak, et al.
Publicado: (2020)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Zobacz, jak powstał wszechświat
Publicado: (2009)

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
por: Yang, Shuqun, et al.
Publicado: (2015)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors
por: Bertsias, George
Publicado: (2020)

JAK Kinases in Health and Disease: An Update
por: Laurence, Arian, et al.
Publicado: (2012)

Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction
por: Liu, Chun-Shan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8ur3g5tcduma0ku85burl506js